BioNTech (NASDAQ:BNTX) Price Target Lowered to $138.00 at Jefferies Financial Group

BioNTech (NASDAQ:BNTX) had its price objective trimmed by Jefferies Financial Group from $151.00 to $138.00 in a research report released on Tuesday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently issued reports on BNTX. Leerink Partners downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. HC Wainwright restated a “buy” rating and set a $140.00 price objective on shares of BioNTech in a report on Thursday, December 11th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Finally, UBS Group upgraded BioNTech to a “hold” rating in a report on Thursday, December 4th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.00.

BioNTech Stock Performance

NASDAQ BNTX opened at $83.89 on Tuesday. The business’s 50-day moving average price is $106.73 and its 200 day moving average price is $102.83. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a market capitalization of $18.89 billion, a PE ratio of -31.90 and a beta of 1.51.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC lifted its position in shares of BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG bought a new stake in BioNTech in the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd raised its stake in BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares in the last quarter. Financial Consulate Inc. acquired a new stake in BioNTech during the third quarter valued at approximately $36,000. Finally, Huntington National Bank lifted its holdings in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after buying an additional 380 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Company ends FY2025 with a very strong cash position (cash, cash equivalents and securities ~€17.2B), which management says de‑risks execution and funds pipeline investments. Press Release
• Positive Sentiment: BioNTech highlighted multiple upcoming oncology catalysts — six late‑stage readouts expected in 2026 and large Phase 3 activity for the PD‑L1/VEGF‑A bispecific (pumitamig) in partnership with Bristol Myers — providing potential upside if trials read out positively. Press Release
• Positive Sentiment: Q4 results beat near‑term expectations on both EPS and revenue (Q4 revenue ~$1.06B vs. ~$942M consensus; EPS loss narrower than expected), showing operational resilience despite YoY revenue declines. Earnings Highlights
• Neutral Sentiment: Co‑founders will form an independent next‑generation mRNA company; BioNTech will contribute certain rights/technologies and take a minority stake with potential milestone and royalty upside — the deal reduces internal focus on those programs but preserves some upside. Company Announcement
• Neutral Sentiment: Jefferies trimmed its price target (from $151 to $138) but kept a Buy rating, signaling some analyst confidence in longer‑term upside despite the reset. Analyst Note
• Negative Sentiment: Founders Şahin and Türeci plan to depart by end‑2026 to start a new mRNA firm; markets treated the leadership exit as a governance and continuity risk, triggering selling pressure. Reuters
• Negative Sentiment: FY2026 revenue guidance was reduced to €2.0–2.3B (well below street expectations), and management signaled higher near‑term R&D/SG&A, which drove concern about near‑term growth and profitability. Guidance & Results
• Negative Sentiment: FY2025 reported a net loss (€1.1B) and a ~24% YoY revenue decline, highlighting the post‑COVID transition and amplifying sensitivity to guidance and leadership changes. Financials
• Negative Sentiment: A shareholder law firm announced an investigation into potential claims related to executive conduct, which can add legal overhang and investor uncertainty. Legal Notice

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.